Phase II Study of Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in Patients With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
Summary
3/30/2021 Note: Trial is close to meeting enrollment; please contact site.
The purpose of this phase II study is to investigate if nivolumab given with tadalafil and vancomycin causes liver cancer to shrink.
General Information
NCT#: NCT03785210
Study ID: 190033
Trial Phase: Phase II
Trial Sponsor: National Cancer Institute (NCI)
Therapies Used in This Trial: Tadalafil, Nivolumab, Vancomycin